+1-518-621-2074 | US-Canada Toll Free Contact Us

Introduction of Gene Therapy and Fetal Hemoglobin Inducers to Encourage Global Thalassemia Market’s Growth

about us

Published on : Jun 16, 2016

ALBANY, New York, June 16, 2016: ResearchMoz.us announces the addition of a new market research study to its huge repository of research reports. The research report, titled “Global Thalassemia Market Report: 2016 Edition,” presents a detailed analysis of the market, including the key growth drivers, restraints, product segmentation, major geographical segments, and competitive scenario. The 45-page research study also offers the potential opportunities and current trends in the global thalassemia market in the forecast period.

Furthermore, the past performance of the global thalassemia market has been presented along with the future projections. The study makes use of several analytical tools to determine the key growth factors that are expected to impact the global market positively as well as negatively. The insightful inputs given by the professionals and industry experts are anticipated to help the new as well as existing players in designing effective business policies.

Thalassemia is a genetic blood disorder characterized by fewer red blood cells and less hemoglobin in a person’s body than normal count. The reduced numbers leads to unwarranted damage of red blood cells resulting in anemia. On the basis of proteins, thalassemia has been broadly divided into alpha thalassemia, beta thalassemia, and sickle beta thalassemia. The latter type is a combination of sickle cells disorder and beta thalassemia. Thalassemia is considered as a rare genetic disorder; however, in the last few years, the number of people affected by thalassemia has been growing significantly. 

Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=725246

Thalassemia can cause several complications such as bone deformities, iron overload, and cardiovascular illness. Patients who have thalassemia minor do not have any threat to life and occasionally need to undergo blood transfusion. On the other hand, thalassemia major patients require periodic blood transfusions to lead a normal life. Thalassemia major in infants mostly leads to stillbirth or may cause death soon after the baby’s birth. At present, thalassemia has only one cure, which is a bone marrow transplantation treatment. This therapy is carried out typically for those who have a severe case of thalassemia.

The increasing research and development activities and spending on stem cell therapy and increasing healthcare expenditure are the key factors projected to fuel the growth of the global thalassemia market throughout the forecast period. In addition, the introduction of fetal hemoglobin inducers and advances in iron chelation therapy are anticipated to create potential opportunities in the next few years. Gene therapy for curing thalassemia is also one of the current trends driving the global thalassemia market. On the other hand, the lack of alternative treatments, high cost of therapies, and unmet market of the Asia Pacific are the key factors hampering the growth of the market.

The research report provides a competitive study of global thalassemia market and analyzes the major players in depth. As per the study, the global thalassemia market is extremely competitive, comprising several players operating in the market. Some of the leading players mentioned in the study are BlueBird Bio, Sangamo Biosciences, Acceleron Pharma, and Lonza group.

To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]